Ultragenyx Pharmaceutical Inc (RARE) Tuesday announced a loss for the first quarter that narrowed from last year driven by revenue growth.
The company's loss was $151.1 million or $1.57 per share, compared to a net loss of $170.7 million or $2.03 per share last year.
The company's revenue for the period rose to $139.3 million from $108.8 million last year.
Looking forward to the full year 2025, the company expects revenues of $640 million to $670 million, Crysvita revenue to be in the range of $460 million to $480 million and Dojolvi revenue to be in the range of $90 million to $100 million.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.